Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Angelo Valerio MarzanoGiovanni GenoveseG CasazzaM T FierroP DapavoN CrimiS FerrucciP PepeS LiberatiP D PigattoA OffidaniE MartinaG GirolomoniM RovarisC FotiL StingeniA CristaudoG W CanonicaE NettisR AseroPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2018)
Our study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bd-dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.
Keyphrases